Evofem Biosciences, Inc. Stock

$0.01

2.11% yesterday

Nasdaq, Jun 27, 05:10 pm CET

ISIN

US30048L1044

Symbol

EVFM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Evofem Biosciences, Inc. Stock price

$0.01

-5,249.99 100.00% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.00 1.05%

ISIN

US30048L1044

Symbol

EVFM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.1m

Enterprise Value

$46.4m

Net debt

$45.3m

Cash

$350.0k

Shares outstanding

113.4m

Valuation (TTM | estimate)

P/E

- | -

P/S

0.06 | -

EV/Sales

2.79 | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-279.44%

Return on Equity

13.49%

ROCE

7.77%

ROIC

67.14%

Debt/Equity

-0.70

Financials (TTM | estimate)

Revenue

$16.6m | -

EBITDA

$-3.7m | -

EBIT

$-4.5m

Net Income

$-3.2m | -

Free Cash Flow

$-3.5m

Growth (TTM | estimate)

Revenue

3.75% | -

EBITDA

78.30% | -

EBIT

73.67%

Net Income

-106.65% | -

Free Cash Flow

11.99%

Margin (TTM | estimate)

Gross

78.83%

EBITDA

-22.06% | -

EBIT

-27.13%

Net

-19.01% | -

Free Cash Flow

-20.76%

EPS

$0.00

FCF per Share

$-0.03

Short interest

11.01%

Employees

32.00

Rev per Employee

$610.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Evofem Biosciences, Inc. Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Evofem Biosciences, Inc. forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Evofem Biosciences, Inc. forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Evofem Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	17 17	4% 4% 100%
- Direct Costs	3.52 3.52	40% 40% 21%
Gross Profit	13 13	28% 28% 79%
- Selling and Administrative Expenses	21 21	16% 16% 124%
- Research and Development Expense	1.25 1.25	58% 58% 8%
EBITDA	-3.66 -3.66	78% 78% -22%
- Depreciation and Amortization	0.84 0.84	250% 250% 5%
EBIT (Operating Income) EBIT	-4.51 -4.51	74% 74% -27%
Net Profit	-3.16 -3.16	107% 107% -19%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Evofem Biosciences, Inc. Stock News

Neutral

PRNewsWire

●

5 days ago

Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store

— Pharma 1 Will Place Launch Quantity Order for PHEXXI in July 2025 — — Commercial Launch in UAE Targeted for Q1 2026 — SAN DIEGO , June 23, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) announced today that private Emirati health care company Pharma 1 Drug Store LLC has filed an application with the United Arab Emirates (UAE) Ministry of Health and Preven...

Neutral

Business Wire

●

19 days ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt's Board of Directors. “We believe that Saundra's background as a CEO and entrepreneur, coupled with her de...

Neutral

PRNewsWire

●

about one month ago

Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1

— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO , May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to SOLOSEC® (secnidazole) 2 g oral gran...

More Evofem Biosciences, Inc. News

Company Profile

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.

Head office	United States
CEO	Saundra Pelletier
Employees	32
Founded	2007
Website	www.evofem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now